Project challenge: Seven stage sequence involving protection-deprotection sequence, labile intermediates and signicant by-product formation with low yield. Solution design:
Salient features of the approach:
Identication of suitable protecting groups and deprotecting reagents and reaction conditions to optimize the yield Route developed was implemented in manufacturing plant and process validation performed
Effective purication techniques including crystallization resulted in control of unknown impurities and generated quality product, meeting ICH specications Conclusion: This case study exemplies the technical abilities of our team in route scouting and developing a process that can be implemented on scale and creating value to the customer in terms of cost and time.
Contact Us
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.
Leaving already?
Don't forget to join us at
CPHI Worldwide 2023.
October 24th-26th, 2023 | Barcelona, Spain
Get ready to accelerate your drug’s journey to the market